Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26

Table 1 Constitutive expression and decrease of CXCR4 at the surface of human colorectal carcinoma cells due to anticancer drugs

Cell line	Basal CXCR4 expression (cpm/10⁵ cells)	Drug treatment
		5-FU	Cis	Vin	MTX
		Maximal decrease (% from control)
HT-29	470 ± 52	75 ± 6.1*	72 ± 6.3*	75 ± 12*	56 ± 7.6*
T84	220 ± 53	42 ± 15	48 ± 22	27 ± 4.4	39 ± 21
HRT-18	62 ± 27	59 ± 18	29 ± 11	76 ± 8.4	63 ± 27
SW480	230 ± 41	24 ± 13	32 ± 13	71 ± 7.6*	24 ± 6.4
SW620	80 ± 29	70 ± 7.0	77 ± 13*	72 ± 18	73 ± 3.0

The relative basal cell-surface protein expression for each cell line was summarized from 8–28 independent experiments. Cells were treated with drugs (5-FU, 5-fluorouracil [0.1 – 1,000 μg/mL]; Cis, cisplatin [0.001 – 10 μg/mL]; Vin, vinblastine [0.001 – 10 μg/mL]; MTX, methotrexate [0.1 – 1,000 μg/mL]) and cell surface expression of CXCR4 was determined by radioimmunobinding assay 48 h later. Maximal decrease of CXCR4 was recorded from 3–8 independent dose–response experiments for each drug and cell line. Data are shown as mean % decreases ± SE. *, significant % decrease due to drug, P < 0.05 using paired t-test

ISSN: 1471-2407